



RESEARCH REPORT



Molecular Diagnostics for Infectious Disease

By Syndrome, Plex, Place and by Country.

With Analysis and Executive Guides.

2023 - 2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	27
1.1	Strategic Situation Analysis.....	28
1.2	Guide for Executives and Business Development Staff.....	30
1.3	Guide for Management Consultants and Investment Advisors.....	31
2	Introduction and Market Definition	33
2.1	What are Molecular Diagnostics?	34
2.2	The Diagnostics Revolution.....	35
2.3	Market Definition.....	37
2.3.1	Revenues.....	37
2.4	Methodology.....	39
2.4.1	Methodology.....	39
2.4.2	Sources.....	39
2.4.3	Authors	39
2.5	Perspective: Healthcare and the IVD Industry	41
2.5.1	Global Healthcare Spending	41
2.5.2	Spending on Diagnostics	42
2.5.3	Important Role of Insurance for Diagnostics.....	44
3	The Infectious Diseases – Market Analysis by Disease	45
3.1	HIV - Human Immunodeficiency Virus (AIDS)	46
3.1.1	Virology	46

3.1.1.1	Classification	46
3.1.1.2	Structure and genome.....	47
3.1.1.3	Tropism.....	50
3.1.1.4	Replication cycle.....	52
3.1.1.5	Genetic variability	58
3.1.2	Diagnosis	59
3.1.3	Testing.....	61
3.1.3.1	Antibody tests	61
3.1.3.2	Point of Care Tests (POCT)	64
3.1.3.3	Antigen Tests	67
3.1.3.4	Nucleic acid-based tests (NAT)	67
3.1.3.5	Other tests used in HIV treatment.....	68
3.1.4	Market Opportunity Analysis	69
3.2	HBV – Hepatitis B.....	74
3.2.1	Virology	75
3.2.1.1	Genome	76
3.2.1.2	Pathogenesis.....	77
3.2.1.3	Hepatitis B virus replication	77
3.2.1.4	Serotypes and genotypes.....	78
3.2.2	Mechanisms.....	78
3.2.3	Diagnosis	79
3.2.4	Market Opportunity Analysis	80
3.3	HCV – Hepatitis C.....	82
3.3.1	Taxonomy.....	83

3.3.2	Structure	84
3.3.2.1	Genome	84
3.3.3	Molecular biology	85
3.3.4	Replication.....	87
3.3.5	Genotypes	88
3.3.5.1	Clinical importance.....	89
3.3.6	Market Opportunity Analysis	89
3.4	HPV - Human papillomavirus.....	91
3.4.1	Virology	93
3.4.1.1	E6/E7 proteins.....	93
3.4.1.2	Role in cancer.....	93
3.4.1.3	E2 research.....	94
3.4.1.4	Latency period	96
3.4.1.5	Clearance	96
3.4.2	Diagnosis	96
3.4.2.1	Cervical testing.....	96
3.4.2.2	Oral testing	98
3.4.2.3	Testing men	98
3.4.2.4	Other testing	100
3.4.3	Market Opportunity Analysis	100
3.5	Influenza.....	106
3.5.1	Virology	108
3.5.1.1	Types of virus	108
3.5.1.2	Influenzavirus A	108

3.5.1.3	Influenzavirus B.....	109
3.5.1.4	Influenzavirus C.....	109
3.5.1.5	Structure, properties, and subtype nomenclature.....	109
3.5.1.6	Replication.....	111
3.5.2	Testing.....	113
3.5.2.1	Advantages/Disadvantages of Molecular Assays.....	115
3.5.3	Market Opportunity Analysis.....	116
3.6	CTGC - Chlamydia/Gonorhea.....	126
3.6.1	Gonorrhea.....	126
3.6.1.1	Diagnosis.....	127
3.6.1.2	Screening.....	127
3.6.2	Chlamydia.....	127
3.6.2.1	Diagnosis.....	128
3.6.2.2	Screening.....	129
3.6.3	Testing.....	130
3.6.3.1	Nucleic acid amplification tests (NAATs).....	130
3.6.3.2	Performance of NAAT Tests.....	139
3.6.4	Market Opportunity Analysis.....	140
3.7	Tuberculosis.....	142
3.7.1	Mycobacteria.....	143
3.7.2	Diagnosis.....	145
3.7.2.1	Active tuberculosis.....	145
3.7.2.2	Latent tuberculosis.....	145
3.7.3	Epidemiology.....	146

3.7.4	Molecular Diagnostic Tests	148
3.7.5	Market Opportunity Analysis	149
3.8	MRSA - Methicillin-resistant Staphylococcus aureus	151
3.8.1	Diagnosis	151
3.8.2	FDA Approved Molecular Tests	152
3.8.3	Market Opportunity Analysis	153
3.9	VRE - Vancomycin-resistant Enterococcus.....	155
3.9.1	FDA Approved MDx Tests for VRE.....	156
3.9.2	Market Opportunity Analysis	157
3.10	Blood Screening	158
3.10.1	Collection and Testing	158
3.10.2	FDA Approved Multiplex Assays.....	159
3.10.3	Market Opportunity Analysis	161
3.11	COVID-19	162
3.11.1	Signs and symptoms.....	163
3.11.2	Transmission.....	165
3.11.3	Diagnosis	166
3.11.4	Prevention	168
3.11.5	Management	169
3.11.6	Prognosis	170
3.12	Pandemic Diagnostics.....	171
3.12.1	Risk Management – Spark and Spread	171
3.12.2	Dx Technology – Nucleic Acid Based.....	173
3.12.3	Dx Technology - Immunoassay & Serology	174

3.12.4	Time to Market and Preparedness Issues	175
3.12.5	Unrecognized Role of Multiplex in Pandemic Mangement.....	175
4	Industry Overview.....	177
4.1	Players in a Dynamic Market.....	178
4.1.1	Academic Research Lab	179
4.1.2	Diagnostic Test Developer.....	180
4.1.3	Instrumentation Supplier	180
4.1.4	Chemical/Reagent Supplier.....	180
4.1.5	Pathology Supplier	181
4.1.6	Independent Clinical Laboratory	181
4.1.7	Public National/regional Laboratory	181
4.1.8	Hospital Laboratory	182
4.1.9	Physicians Office Lab (POLs)	182
4.1.10	Audit Body	183
4.1.11	Certification Body.....	183
4.2	The Clinical Laboratory Market Segments	185
4.2.1	Traditional Market Segmentation.....	185
4.2.2	Laboratory Focus and Segmentation.....	187
4.3	Industry Structure.....	189
4.3.1	Hospital Testing Share	189
4.3.2	Economies of Scale.....	189
4.3.2.1	Hospital vs. Central Lab.....	190
4.3.3	Physician Office Lab's.....	191
4.3.4	Physician's and POCT	191

5	Profiles of Key MDx Companies	193
5.1	1928 Diagnostics.....	194
5.2	Abacus Diagnostica	195
5.3	Abbott Laboratories.....	196
5.4	Accelerate Diagnostics	198
5.5	Access Bio.....	199
5.6	Ador Diagnostics	200
5.7	ADT Biotech	201
5.8	Akonni Biosystems	202
5.9	Altona Diagnostics	203
5.10	Alveo Technologies.....	204
5.11	Anatolia Geneworks	205
5.12	Anitoo.....	206
5.13	Antelope Dx.....	207
5.14	Applied BioCode.....	208
5.15	Assurance Scientific Laboratories	210
5.16	Aureum Diagnostics	211
5.17	Aus Diagnostics	212
5.18	Beckman Coulter Diagnostics.....	213
5.19	Becton, Dickinson and Company	214
5.20	Binx Health	216
5.21	Biocartis.....	218
5.22	BioFire Diagnostics (bioMérieux)	219
5.23	bioMérieux Diagnostics.....	221

5.24	Bio-Rad Laboratories, Inc.....	224
5.25	Bosch Healthcare Solutions GmbH.....	226
5.26	Celemics	227
5.27	Cepheid (Danaher)	228
5.28	Chembio.....	230
5.29	Co Diagnostics	231
5.30	Credo Diagnostics Biomedical	232
5.31	Cue Health.....	233
5.32	Curetis N.V. / Curetis GmbH.....	235
5.33	Detect	236
5.34	Diagenode Diagnostics	237
5.35	Diascopic	238
5.36	Diasorin S.p.A.....	239
5.37	Domus Diagnostics.....	241
5.38	Eiken Chemical	242
5.39	Element Biosciences	243
5.40	Enzo Biochem	244
5.41	Eurofins Scientific	246
5.42	Fluxergy	248
5.43	Fulgent Genetics	249
5.44	Fusion Genomics.....	250
5.45	Genedrive.....	252
5.46	Genetic Signatures.....	253
5.47	GenMark Dx (Roche)	254

5.48	Genomadix.....	256
5.49	Grifols.....	257
5.50	Grip Molecular Technologies	258
5.51	Hibergene Diagnostics.....	259
5.52	Hologic	260
5.53	Illumina	262
5.54	Immunexpress.....	263
5.55	Inflammatix	264
5.56	Invetech.....	265
5.57	Janssen Diagnostics	266
5.58	Karius	267
5.59	Lexagene	269
5.60	LightDeck Diagnostics	270
5.61	Lucira Health.....	271
5.62	Luminex Corp (DiaSorin)	272
5.63	LumiraDx	274
5.64	Lumos Diagnostics.....	275
5.65	Mammoth Biosciences	276
5.66	Maxim Biomedical	277
5.67	Meridian Bioscience.....	278
5.68	Mesa Biotech (Thermo Fisher)	280
5.69	MicroGem.....	281
5.70	Millipore Sigma	282
5.71	Mindray	283

5.72	Minute Molecular	284
5.73	Mobidiag (Hologic)	285
5.74	Molbio Diagnostics	286
5.75	NanoDx	287
5.76	Nanomix	288
5.77	Novacyt	289
5.78	Novel Microdevices	290
5.79	OnsiteGene	291
5.80	Operon	292
5.81	Oxford Nanopore Technologies	293
5.82	Panagene	294
5.83	Pathogenomix	295
5.84	Perkin Elmer	296
5.85	Prenetics	298
5.86	Primerdesign (Novacyt)	299
5.87	Prominex	300
5.88	Proof Diagnostics	302
5.89	Qiagen	303
5.90	QuantuMDx	305
5.91	Quest Diagnostics	306
5.92	QuidelOrtho	307
5.93	Randox Toxicology	309
5.94	Roche Molecular Diagnostics	310
5.95	Saw Diagnostics	312

5.96	Scope Fluidics	313
5.97	SD Biosensor	314
5.98	Seegene.....	316
5.99	Siemens Healthineers	318
5.100	Singular Genomics	319
5.101	SomaLogic	321
5.102	Sona Nanotech	322
5.103	SpeedX.....	323
5.104	T2 Biosystems.....	324
5.105	Talis Biomedical	325
5.106	Thermo Fisher Scientific Inc.....	326
5.107	Ultima Genomics	329
5.108	Vela Diagnostics.....	330
5.109	Veramarx	331
5.110	Veredus Laboratories.....	332
5.111	Vir.....	333
5.112	Vircell.....	334
5.113	Visby Medical	335
5.114	XCR Diagnostics	337
5.115	YD Diagnostics.....	338
5.116	Zhejiang Orient Gene Biotech	340
6	Market Trends	342
6.1	Factors Driving Growth	343
6.1.1	New Genotypes Creating New Markets	344

6.1.2	The Aging Effect	344
6.1.3	Developing World Driving ID Dx Growth.....	346
6.1.4	Point of Care – Why Centralization is Losing Steam	346
6.1.5	Self Testing.....	347
6.1.6	The Need for Speed	347
6.1.7	The COVID Pandemic.....	347
6.2	Factors Limiting Growth	349
6.2.1	Lower Costs.....	349
6.2.2	Infectious Disease is Declining.....	351
6.2.3	Wellness Hurts.....	351
6.2.4	Economic Growth improves Living Standards	351
6.3	Instrumentation and Automation	352
6.3.1	Instruments Key to Market Share.....	352
6.3.2	The Shrinking Machine	352
6.3.3	Multiplex, Point of Care and The Speed Factor.....	352
6.4	Diagnostic Technology Development	354
6.4.1	The Sepsis Testing Market – A New Direction?	355
6.4.2	POCT/Self Testing as a Disruptive Force	355
6.4.3	The Genetics Play – One Test for All Known Infections.....	356
6.4.4	Antibiotic Resistance Genes – Simplifying Diagnostics.....	356
7	Molecular Dx – Infectious Disease Recent Developments	357
7.1	Recent Developments – Importance and How to Use This Section	358
7.1.1	Importance of These Developments	358
7.1.2	How to Use This Section.....	358

7.2	Compact POCT Platform Unlocks Multiplexing Potential of Real-Time PCR	358
7.3	Takara Bio and BioExcel Partner on ID Panels	359
7.4	BioGX introduces pixl real-time PCR platform.....	360
7.5	Sherlock Biosciences Adds Ambient Amplification to Infectious Disease Diagnostic Toolkit.....	361
7.6	Climate change is making hundreds of diseases much worse.....	365
7.7	BioMérieux Invests in Sepsis Dx Startup Weezion.....	367
7.8	Domus Diagnostics to Launch POC MDx Test System.....	368
7.9	Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC	371
7.10	Oxford Nanopore Diagnostics to Develop Clinical Tools.....	374
7.11	Pathogenomix Developing Infectious Disease Platform Using NGS	377
7.12	COVID-19 Accelerating Trend Toward Pharmacy-Based Testing	382
7.13	Co-Diagnostics Seeks FDA EUA for At-Home PCR Diagnostic	385
7.14	Sense Biodetection to Debut Instrument-Free Point-of-Care MDx.....	390
7.15	Home Test Company Prenetics to go Public	394
7.16	Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio.....	395
7.17	Lucira Health Posts Revenue Growth on OTC C19 Test	395
7.18	BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform	397
7.19	Talis Biomedical Discusses Point-of-Care	400
7.20	Roche to Acquire GenMark Diagnostics for \$1.8B	405
7.21	Pandemic Pushes Handheld qPCR Devices Closer to Commercialization.....	406
7.22	Hologic to Acquire Mobidiag	413
7.23	Lucira Health Focuses on User Friendly Approach to Home Testing	414
7.24	Infectious Disease Dx Firm Talis Biomedical Raises \$254M in IPO.....	420

7.25	Fluidigm Plans 'Durable' Diagnostics, Clinical Business	421
7.26	Thermo Fisher Scientific to Acquire Mesa Biotech for Up to \$550M	424
7.27	Mammoth Biosciences Developing Pathogen Detection Tech	425
7.28	Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests	428
7.29	Scanogen Developing 90 Minute Infection Test.....	433
7.30	Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection	436
7.31	FDA Provides Self Testing SARS-CoV-2 EAU Guidance	439
7.32	Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic	441
7.33	Genetic Signatures Gets CE Mark for Coronavirus Molecular Test	443
7.34	Qiagen Respiratory Panel with Coronavirus Receives CE Mark.....	444
7.35	Lumos Diagnostics Closes \$15M Series A Funding	445
7.36	Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay	445
8	The Global Market for Molecular Diagnostics Infectious Disease	447
8.1	Global Market Overview by Country	448
8.1.1	Table – Global Market by Country.....	448
8.1.2	Chart - Global Market by Country	449
8.2	Global Market by Syndrome - Overview	450
8.2.1	Table – Global Market by Syndrome	450
8.2.2	Chart – Global Market by Syndrome – Base/Final Year Comparison	451
8.2.3	Chart – Global Market by Syndrome – Base Year	452
8.2.4	Chart – Global Market by Syndrome – End Year.....	453
8.2.5	Chart – Global Market by Syndrome – Share by Year	454
8.2.6	Chart – Global Market by Syndrome – Segments Growth.....	455
8.3	Global Market by Plex - Overview	456

8.3.1	Table – Global Market by Plex.....	456
8.3.2	Chart – Global Market by Plex – Base/Final Year Comparison	457
8.3.3	Chart – Global Market by Plex – Base Year.....	458
8.3.4	Chart – Global Market by Plex – End Year	459
8.3.5	Chart – Global Market by Plex – Share by Year.....	460
8.3.6	Chart – Global Market by Plex – Segments Growth.....	461
8.4	Global Market by Place - Overview	462
8.4.1	Table – Global Market by Place.....	462
8.4.2	Chart – Global Market by Place – Base/Final Year Comparison	463
8.4.3	Chart – Global Market by Place – Base Year.....	464
8.4.4	Chart – Global Market by Place – End Year	465
8.4.5	Chart – Global Market by Place – Share by Year.....	466
8.4.6	Chart – Global Market by Place – Segments Growth	467
9	Global MDx Infectious Disease Markets – By Syndrome	468
9.1	Respiratory	469
9.1.1	Table Respiratory – by Country	469
9.1.2	Chart - Respiratory Growth.....	470
9.2	Gastrointestinal.....	471
9.2.1	Table Gastrointestinal – by Country	471
9.2.2	Chart - Gastrointestinal Growth	472
9.3	Blood	473
9.3.1	Table Blood – by Country	473
9.3.2	Chart - Blood Growth.....	474
9.4	Meningitis/Encephalitis	475

9.4.1	Table Meningitis/Encephalitis – by Country.....	475
9.4.2	Chart - Meningitis/Encephalitis Growth.....	476
9.5	Sexually Transmitted Disease.....	477
9.5.1	Table Sexually Transmitted Disease – by Country.....	477
9.5.2	Chart – Sexually Transmitted Disease Growth.....	478
9.6	Other.....	479
9.6.1	Table Other – by Country.....	479
9.6.2	Chart - Other Growth.....	480
10	Global MDx Markets for Infectious Disease – by Plex.....	481
10.1	Single Plex.....	482
10.1.1	Table Single Plex – by Country.....	482
10.1.2	Chart - Single Plex Growth.....	483
10.2	Duplex.....	484
10.2.1	Table Duplex – by Country.....	484
10.2.2	Chart - Duplex Growth.....	485
10.3	Triplex.....	486
10.3.1	Table Triplex – by Country.....	486
10.3.2	Chart - Triplex Growth.....	487
10.4	Multiplex Technology.....	488
10.4.1	Table Multiplex – by Country.....	488
10.4.2	Chart - Multiplex Growth.....	489
11	Global MDx Infectious Disease Markets – by Place.....	490
11.1	Hospital Lab.....	491
11.1.1	Table Hospital Lab – by Country.....	491

- 11.1.2 Chart - Hospital Lab Growth..... 492
- 11.2 Outpatient Lab..... 493
 - 11.2.1 Table Outpatient Lab – by Country 493
 - 11.2.2 Chart - Outpatient Lab Growth 494
- 11.3 POC 495
 - 11.3.1 Table POC – by Country 495
 - 11.3.2 Chart - POC Growth..... 496
- 11.4 Other Place 497
 - 11.4.1 Table Other Place– by Country..... 497
 - 11.4.2 Chart – Other Place Growth..... 498
- 12 Appendices499
 - 12.1 United States Medicare System: Clinical Laboratory Fees Schedule 500
 - 12.2 The Most Used IVD Assays..... 611
 - 12.3 The Highest Grossing Assays 616

Table of Tables

Table 1 Classification of HIV Species.....	47
Table 2 HIV Tests - CMS Codes & Prices	70
Table 3 Current HIV Molecular Tests and Instruments Used.....	71
Table 4 HBV Tests - CMS Codes & Prices	82
Table 5 HCV Tests - CMS Codes & Prices	90
Table 6 HPV Clearance Rates	96
Table 7 HPV Tests - CMS Codes & Prices.....	101
Table 8 HPV Tests, Technology, Types	102
Table 9 Types of Influenza Tests	114
Table 10 Influenza Tests - CMS Codes & Prices.....	117
Table 11 FDA Cleared Molecular Assays for Influenza	118
Table 12 FDA Cleared NAAT CTGC Tests	132
Table 13 CTGC NAAT Target Sequences and Possible False Reactions	136
Table 14 CTGC Tests - CMS Codes & Prices.....	141
Table 15 FDA Approved MDx Tests for Tuberculosis.....	148
Table 16 Tuberculosis Tests - CMS Codes & Prices.....	149
Table 17 FDA Approved Tests for MRSA	152
Table 18 MRSA Tests - CMS Codes & Prices	154
Table 19 FDA Approved Tests for VRE	156
Table 20 VRE Tests - CMS Codes & Prices	157

Table 21 FDA Approved Multiplex Assays.....	159
Table 22 Characteristics of Coronavirus Pandemic Infections	162
Table 23 COVID-19 Symptoms.....	164
Table 24 Market Players by Type	179
Table 25 Clinical Laboratory Departments and Segments	186
Table 26 Laboratory Management Focus – Different Approaches	187
Table 27 Key Segmentation Variables Going Forward.....	188
Table 28 Five Factors Driving Growth	343
Table 29 Four Factors Limiting Growth	349
Table 30 Key Diagnostic Laboratory Technology Trends	354
Table 31 - Global Market by Region	448
Table 32 Global Market by Syndrome	450
Table 33 Global Market by Plex.....	456
Table 34 Global Market by Place.....	462
Table 35 Respiratory by Country.....	469
Table 36 Gastrointestinal by Country	471
Table 37 Blood by Country.....	473
Table 38 Meningitis/Encephalitis by Country.....	475
Table 39 Sexually Transmitted Disease by Country	477
Table 40 Other by Country.....	479
Table 41 Single Plex by Country.....	482
Table 42 Duplex by Country	484
Table 43 Triplex by Country	486
Table 44 Multiplex by Country	488

Table 45 Hospital Lab by Country	491
Table 46 Outpatient Lab by Country	493
Table 47 POC by Country	495
Table 48 Other Place by Country	497
Table 49 Clinical Lab Fee Schedule	500
Table 50 The Most Common Assays.....	611
Table 51 Largest Revenue Assays.....	616

Table of Figures

Figure 1 global Healthcare Spending.....	42
Figure 2 The Lab Test Pie	43
Figure 3 HIV Virion	48
Figure 4 Diagram of the HIV Replication Cycle	52
Figure 5 The Structure of the HBV Virus.....	76
Figure 6 Hepatitis B Replication	77
Figure 7 Structure of the HCV Virus.....	84
Figure 8 HCV Replication Cycle	87
Figure 9 Structure of the Influenza Virion	110
Figure 10 Influenza Replication.....	111
Figure 11 Scanning Electronmicrograph of Tuberculosis.....	144
Figure 12 The Road to Diagnostics	178
Figure 13 The Changing Age of The World's Population.....	345
Figure 14 Health Care Consumption by Age	345
Figure 15 Cancer Incidence by Age	346
Figure 16 Chart Infectious Disease Decline	350
Figure 17 Global Market Shares Chart.....	449
Figure 18 Global Market by Syndrome - Base vs. Final	451
Figure 19 Global Market by Syndrome Base Year	452
Figure 20 Global Market by Syndrome End Year	453
Figure 21 Syndrome Share by Year	454

Figure 22 Syndrome Segments Growth.....	455
Figure 23 Global Market by Plex - Base vs. Final.....	457
Figure 24 Global Market by Plex Base Year.....	458
Figure 25 Global Market by Plex End Year	459
Figure 26 Plex Share by Year.....	460
Figure 27 Plex Segments Growth.....	461
Figure 28 Global Market by Place - Base vs. Final.....	463
Figure 29 Global Market by Place Base Year.....	464
Figure 30 Global Market by Place End Year	465
Figure 31 Place Share by Year.....	466
Figure 32 Place Segments Growth.....	467
Figure 33 Respiratory Growth.....	470
Figure 34 Gastrointestinal Diagnostics Growth.....	472
Figure 35 Blood Growth.....	474
Figure 36 Meningitis/Encephalitis Growth.....	476
Figure 37 Sexually Transmitted Disease Growth	478
Figure 38 Other Growth.....	480
Figure 39 Single Plex Growth.....	483
Figure 40 Duplex Growth.....	485
Figure 41 Triplex Growth	487
Figure 42 Multiplex Growth	489
Figure 43 Hospital Lab Growth.....	492
Figure 44 Outpatient Lab Growth	494
Figure 45 POC Growth.....	496

Figure 46 Other Place Growth 498